ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

ClinicalTrials.gov ID: NCT03773302

Public ClinicalTrials.gov record NCT03773302. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial

Study identification

NCT ID
NCT03773302
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Enrollment
48 participants

Conditions and interventions

Interventions

  • BGJ398 Drug
  • Cisplatin Drug
  • Gemcitabine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 26, 2019
Primary completion
Mar 1, 2023
Completion
Mar 1, 2023
Last update posted
May 7, 2024

2019 – 2023

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Banner MD Anderson Cancer Center Gilbert Arizona 85234
University of Arizona Tucson Arizona 85724
University of Arkansas for Medical Sciences Little Rock Arkansas 72205
St. Joseph Heritage Healthcare Fullerton California 92835
USC Norris Cancer Center Los Angeles California 90033
University of California Los Angeles Los Angeles California 90095
Florida Hospital Medical Group Orlando Florida 32804
UF Health Cancer Center at Orlando Health Orlando Florida 32806
Northwestern Memorial Hospital Chicago Illinois 60611
University Medical Center - New Orleans New Orleans Louisiana 70112
Frederick Regional Healthcare Systems/James M. Stockman Cancer Institute Frederick Maryland 21702
Massachusetts General Hospital Boston Massachusetts 02114
Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment Center Detroit Michigan 48201
Cancer and Hematology Centers of Western Michigan Grand Rapids Michigan 49503
William Beaumont Hospital Royal Oak Michigan 48073
NYU Langone Medical Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10021
Levine Cancer Institute - Charlotte Charlotte North Carolina 28204
University of Cincinnati Medical Center Cincinnati Ohio 45267
Ohio State University Comprehensive Cancer Center Columbus Ohio 43202
Charleston Oncology Charleston South Carolina 29414
Parkland Health and Hospital System Dallas Texas 75343
University of Texas Southwestern Medical Center Dallas Texas 75390
University of Texas MD Anderson Cancer Center Houston Texas 77030
Baylor College of Medicine Houston Texas 77096

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03773302, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2024 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03773302 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →